GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.

Welcome back to Endpoints Weekly. Grab a cup of Saturday morning coffee and let’s dive straight into the news — it was a busy week!

Eli Lilly shares first human trial results for LOXO-435, a selective FGFR3 inhibitor for bladder cancer, showing 41% response ...

The Trump administration’s effort to remake the federal workforce swept through US healthcare agencies on Friday, with wide ...

Johnson & Johnson is set to push for confirmation of a bankruptcy plan next week that would settle a vast majority of cases ...

Major drugmakers are planning to meet with President Donald Trump next week at the White House as part of the industry’s ...

David Schenkein will step down from Agios Phar­ma­ceu­ti­cals ’ board of di­rec­tors at the end of the month “to de­vote more ...

Kojin Therapeutics, a startup attempting to develop new treatments using programmed cell death, left last month’s JP Morgan ...

A series of actions by President Donald Trump's administration have provoked profound anxiety among academic labs that ...

Renee Wegrzyn has been let go as the head of a federal agency that pursues ambitious ideas to accelerate biomedical ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

Corbus' CRB-701 shows 23% response rate in early cancer trial, but shares fall after some patients with prior Padcev ...